Nxstage Medical, Inc. (NXTM) Tops Q4 EPS by 9c, Offers Weak Q1 and FY12 Guidance
Tweet
Share
E-mailGet Alerts NXTM Hot Sheet
Join SI Premium – FREE
Nxstage Medical, Inc. (NASDAQ: NXTM) reported Q4 EPS of $0.00, $0.09 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $57 million versus the consensus estimate of $56.21 million.
Nxstage Medical, Inc. sees Q1 2012 EPS of $-0.11-$-0.09, versus the consensus of $-0.06. Nxstage Medical, Inc. sees Q1 2012 revenue of $56-$57 million, versus the consensus of $57 million.
Nxstage Medical, Inc. sees FY2012 EPS of $-0.32-$-0.25, versus the consensus of $-0.13. Nxstage Medical, Inc. sees FY2012 revenue of $240-$245 million, versus the consensus of $245.13 million.
For earnings history and earnings-related data on Nxstage Medical, Inc. (NXTM) click here.
Nxstage Medical, Inc. sees Q1 2012 EPS of $-0.11-$-0.09, versus the consensus of $-0.06. Nxstage Medical, Inc. sees Q1 2012 revenue of $56-$57 million, versus the consensus of $57 million.
Nxstage Medical, Inc. sees FY2012 EPS of $-0.32-$-0.25, versus the consensus of $-0.13. Nxstage Medical, Inc. sees FY2012 revenue of $240-$245 million, versus the consensus of $245.13 million.
For earnings history and earnings-related data on Nxstage Medical, Inc. (NXTM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Okta upgraded as AI security opportunity boosts outlook
- Terreno Realty Corp (TRNO) PT Raised to $75 at KeyBanc on 'Improving Demand'
- NeOnc Phase 2a brain cancer trial shows 48.9% survival vs. 20% benchmark
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
